It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRJF’s FA Score shows that 1 FA rating(s) are green whileMAHLY’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRJF’s TA Score shows that 2 TA indicator(s) are bullish while MAHLY’s TA Score has 3 bullish TA indicator(s).
ARRJF (@Medical Distributors) experienced а 0.00% price change this week, while MAHLY (@Medical Distributors) price change was +3.04% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +0.86%. For the same industry, the average monthly price growth was +2.51%, and the average quarterly price growth was +147.05%.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
ARRJF | MAHLY | ARRJF / MAHLY | |
Capitalization | 1.16B | 3.69B | 32% |
EBITDA | 1.84B | 74B | 2% |
Gain YTD | -19.843 | -0.740 | 2,681% |
P/E Ratio | 33.78 | 13.48 | 251% |
Revenue | 10.5B | 3.35T | 0% |
Total Cash | 1.07B | 252B | 0% |
Total Debt | 1.2B | 30B | 4% |
ARRJF | MAHLY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 29 Undervalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 39 | |
PRICE GROWTH RATING 1..100 | 81 | 55 | |
P/E GROWTH RATING 1..100 | 90 | 76 | |
SEASONALITY SCORE 1..100 | 39 | 11 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRJF's Valuation (29) in the null industry is somewhat better than the same rating for MAHLY (89). This means that ARRJF’s stock grew somewhat faster than MAHLY’s over the last 12 months.
ARRJF's Profit vs Risk Rating (100) in the null industry is in the same range as MAHLY (100). This means that ARRJF’s stock grew similarly to MAHLY’s over the last 12 months.
MAHLY's SMR Rating (39) in the null industry is somewhat better than the same rating for ARRJF (80). This means that MAHLY’s stock grew somewhat faster than ARRJF’s over the last 12 months.
MAHLY's Price Growth Rating (55) in the null industry is in the same range as ARRJF (81). This means that MAHLY’s stock grew similarly to ARRJF’s over the last 12 months.
MAHLY's P/E Growth Rating (76) in the null industry is in the same range as ARRJF (90). This means that MAHLY’s stock grew similarly to ARRJF’s over the last 12 months.
ARRJF | MAHLY | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago28% |
Stochastic ODDS (%) | N/A | 4 days ago38% |
Momentum ODDS (%) | 4 days ago11% | 4 days ago28% |
MACD ODDS (%) | 5 days ago10% | 4 days ago25% |
TrendWeek ODDS (%) | 4 days ago18% | 4 days ago36% |
TrendMonth ODDS (%) | 4 days ago19% | 4 days ago35% |
Advances ODDS (%) | N/A | N/A |
Declines ODDS (%) | N/A | N/A |
BollingerBands ODDS (%) | N/A | N/A |
Aroon ODDS (%) | 4 days ago34% | 4 days ago35% |
A.I.dvisor tells us that ARRJF and SHPMF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARRJF and SHPMF's prices will move in lockstep.
Ticker / NAME | Correlation To ARRJF | 1D Price Change % | ||
---|---|---|---|---|
ARRJF | 100% | N/A | ||
SHPMF - ARRJF | 8% Poorly correlated | N/A | ||
COSM - ARRJF | 5% Poorly correlated | -5.82% | ||
MAHLY - ARRJF | 2% Poorly correlated | N/A | ||
PDRX - ARRJF | 0% Poorly correlated | N/A | ||
MEPDF - ARRJF | 0% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that MAHLY and ZYXI have been poorly correlated (+5% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MAHLY and ZYXI's prices will move in lockstep.
Ticker / NAME | Correlation To MAHLY | 1D Price Change % | ||
---|---|---|---|---|
MAHLY | 100% | N/A | ||
ZYXI - MAHLY | 5% Poorly correlated | -1.79% | ||
PDRX - MAHLY | 2% Poorly correlated | N/A | ||
SHPMF - MAHLY | 2% Poorly correlated | N/A | ||
ARRJF - MAHLY | 2% Poorly correlated | N/A | ||
COSM - MAHLY | 2% Poorly correlated | -5.82% | ||
More |